Generic Name: Beclomethasone Dipropionate
Class: Adrenals
VA Class: NT200
Molecular Formula: C28H37ClO7
CAS Number: 5534-09-8
Introduction
Synthetic corticosteroid;2 149 minimal mineralocorticoid activity.149 a
Uses for QVAR
Asthma
Used for the long-term prevention of bronchospasm in patients with asthma.1 2 8 21 24 25 26 103 112 113 116 144 147 149 152
Should not be used in the treatment of nonasthmatic bronchitis.1 28 112 113 144
Chronic Obstructive Pulmonary Disease
Efficacy in patients with chronic obstructive pulmonary disease (e.g., bronchitis)† who are stabilized with oral corticosteroids33 34 37 117 or whose disease is corticosteroid responsive117 118 remains to be fully evaluated.
Inflammatory Conditions of the GI Tract
Has been used as an oral solution35 or rectal suspension36 (these dosage forms not commercially available in the US) in the management of inflammatory diseases of the GI tract† (e.g., inflammatory bowel disease†, eosinophilic gastroenteritis†).35 36 However, the role of beclomethasone dipropionate in the management of inflammatory conditions of the GI tract remains to be established.35 36
QVAR Dosage and Administration
General
Adjust dosage carefully according to individual requirements and response.1 2 61 83 112 113 144 149
After a satisfactory response is obtained, decrease dosage gradually to the lowest dosage that maintains an adequate clinical response.149 150 Achieve the lowest effective dosage, particularly in children, since inhaled corticosteroids have the potential to affect growth. (See Pediatric Use under Cautions.)149 150
Conversion to Orally Inhaled Therapy in Patients Receiving Systemic Corticosteroids
When switching from systemic corticosteroids to orally inhaled beclomethasone dipropionate, asthma should be reasonably stable before initiating treatment with the oral inhalation.1 2 112 113 144 149
Initially, administer the aerosol concurrently with the maintenance dosage of the systemic corticosteroid.1 2 112 113 144 149 After about 1 week, gradually withdraw the systemic corticosteroid.1 2 112 113 144 149
Death has occurred in some individuals in whom systemic corticosteroids were withdrawn too rapidly.1 2 112 113 144 149 (See Withdrawal of Systemic Corticosteroid Therapy under Warnings.)
If exacerbations of asthma occur after transfer to oral inhalation therapy, administer short courses of systemic corticosteroids, then taper dosage as symptoms subside.1 2 112 113 144 149
Administration
Oral Inhalation
Administer by oral inhalation using an oral aerosol inhaler.149
Test-spray inhalation aerosol (2 times) before first use or whenever the aerosol has not been used for prolonged periods (>10 days).149 b
Oral inhalation aerosol is formulated as a solution, which does not require shaking.149
Exhale slowly and completely and place the mouthpiece of the inhaler well into the mouth with the lips closed firmly around it; keep the tongue below the mouthpiece.b Inhale slowly and deeply through the mouth while actuating the inhaler.b Hold the breath for as long as possible (about 5–10 seconds), withdraw the mouthpiece, and exhale gently.b If additional inhalations are required, repeat the procedure.b
Rinse the mouth thoroughly with water to remove drug deposited in the oropharyngeal area.33 48 49 52 59 149 b
Clean the mouthpiece weeklyb using a clean, dry tissue or cloth.b Do not wash or place any part of the inhaler canister in water.b
Dosage
Available as beclomethasone dipropionate; dosage expressed in terms of the salt.b 149
Oral inhalation aerosol releases 50 or 100 mcg of beclomethasone dipropionate, and delivers 40 or 80 mcg, respectively, from the actuator (mouthpiece) per metered spray.149
Pediatric Patients
Asthma
Oral Inhalation
Children 5–11 years of age receiving bronchodilators alone or inhaled corticosteroids previously: Initially, 40 mcg twice daily.149 If required, dosage may be increased to a maximum 80 mcg twice daily.149
Children ≥12 years of age receiving bronchodilators alone previously: Initially, 40–80 mcg twice daily.149 If required, dosage may be increased to a maximum 320 mcg twice daily.149
Children ≥12 years of age receiving inhaled corticosteroids previously: Initially, 40–160 mcg twice daily. If required, dosage may be increased to a maximum 320 mcg twice daily.
Adults
Asthma
Oral Inhalation
In adults receiving bronchodilators alone previously: Initially, 40–80 mcg twice daily.149 149 If required, dosage may be increased to a maximum 320 mcg twice daily.149
Adults receiving inhaled corticosteroids: Initially, 40–160 mcg twice daily. If required, dosage may be increased to a maximum of 320 mcg twice daily.
Prescribing Limits
Pediatric Patients
Asthma
Oral Inhalation
Children 5–11 years of age: Maximum 80 mcg twice daily.149
Children ≥12 years of age: Maximum 320 mcg twice daily.149
Adults
Asthma
Oral Inhalation
Maximum 320 mcg twice daily.149
Special Populations
Geriatric Patients
Consider initial dosages at the lower end of the usual range due to possible age-related decrease in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.149
Cautions for QVAR
Contraindications
Primary treatment of severe acute asthmatic attacks or status asthmaticus when intensive measures1 2 29 112 113 149 (e.g., oxygen, parenteral bronchodilators, IV corticosteroids)147 are required.
Known hypersensitivity to the drug or any ingredient in the formulation.1 2 112 113 144 149
Warnings/Precautions
Warnings
Withdrawal Of Systemic Corticosteroid Therapy
Possible corticosteroid withdrawal symptoms (e.g., joint pain, muscular pain, lassitude, depression);1 2 112 113 144 149 acute adrenal insufficiency;1 2 112 113 144 life-threatening exacerbation of asthma;1 2 112 113 144 149 pulmonary infiltrates with eosinophilia;1 112 113 or symptomatic exacerbation of allergic conditions1 2 27 44 52 58 70 112 113 144 if prolonged systemic corticosteroid therapy is replaced with oral inhalation corticosteroid therapy.1 2 112 113 144 149 Such symptoms may be observed especially in patients maintained on ≥20 mg of prednisone (or its equivalent) daily and particularly during the later part of the transfer.149
In general, the greater the dosage and duration of systemic corticosteroid therapy, the greater the time required for withdrawal of systemic corticosteroids and replacement by orally inhaled corticosteroids.73
Taper the dosage of the systemic corticosteroid, and carefully monitor patients during dosage reduction for objective signs of adrenal insufficiency (e.g., hypotension, weight loss).1 2 112 113 144 149
Immunosuppressed Patients
Increased susceptibility to infections in patients who are taking immunosuppressant drugs compared with healthy individuals.113 134 135 136 137 138 139 140 141 142 143 144 Certain infections (e.g., varicella [chickenpox], measles) can have a more serious or even fatal outcome in such patients, particularly in children.113 134 135 136 137 138 139 140 141 142 143 144
Exposure to varicella and measles should be avoided in previously unexposed patients.b If exposure to varicella (chickenpox) or measles occurs in susceptible patients, consider administering varicella zoster immune globulin (VZIG) or immune globulin (IG) respectively.b Consider treatment with an antiviral agent if varicella develops.b
Concomitant Therapy
Use with caution in patients receiving systemic prednisone for any disease.45 47 Concomitant use with prednisone in an alternate-day or daily dosing regimen could increase the likelihood of HPA-axis suppression compared with therapeutic dosages of either drug alone.45 47
Resume systemic corticosteroids during periods of stress (e.g., infection, trauma, surgery) or a severe asthma exacerbation in patients who were attempting a switch from systemic to orally inhaled corticosteroid therapy.149
Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression
Avoid higher than recommended dosages of the drug, since suppression of HPA function may occur.149 If higher than recommended dosages are used, carefully consider the relative risks of adrenal suppression and potential therapeutic benefits.149 Recommended dosages of orally inhaled drug provide less than normal physiologic amounts of glucocorticoid systemically and do not provide mineralocorticoid activity.149 Orally inhaled drug will not compensate for insufficient endogenous cortisol production caused by previous systemic corticosteroid therapy.149
Respiratory Effects
Bronchospasm,1 2 57 112 113 133 149 cough,20 25 58 131 132 149 and/or wheezing57 58 131 132 133 149 may occur, especially in asthmatic patients with hyperactive airways.20 25 57 58 101 131 132 133
If bronchospasm occurs, treat immediately with a short-acting bronchodilator, and discontinue treatment with beclomethasone dipropionate and institute alternative therapy.149
Infection
Use with caution, if at all, in patients with clinical tuberculosis or latent M. tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, or parasitic infections; or ocular herpes simplex or untreated, systemic viral infections.1 2 100 144 149
Sensitivity Reactions
Immediate or delayed hypersensitivity reactions, including bronchospasm, anaphylactic/anaphylactoid reactions,2 urticaria, angioedema, and rash reported rarely.1 2 112 113 149
General Precautions
Systemic Corticosteroid Effects
Possible signs and symptoms of Cushing’s syndrome (e.g., hypertension, glucose intolerance, cushingoid features) in patients who are particularly sensitive to corticosteroid effects or when usual dosages of the drug are exceeded.100 149
Carefully monitor neonates exposed to prenatal corticosteroids for manifestations of hypoadrenalism.2 61 112 144 149
Ocular Effects
Glaucoma, increased intraocular pressure, and cataracts reported rarely.149
Other Effects
Unknown long-term, systemic, and local effects of the drug in humans, particularly developmental or immunologic processes in the mouth, pharynx, trachea, and lung.149
Specific Populations
Pregnancy
Category C.149 (See Systemic Corticosteroid Effects under Cautions.)
Lactation
Distributed into milk.144 149 Discontinue nursing or the drug.144 149
Pediatric Use
Safety and efficacy not established in children <5 years of age.149 No overall differences in the pattern, severity, or frequency of adverse events in children 5–12 years of age compared with those in adults.149 Monitor periodically children receiving prolonged therapy for possible adverse effects on growth and development.62 149
Geriatric Use
Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.149
Use caution due to the greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy in geriatric patients.149 (See Geriatric Patients under Dosage and Administration.)
Common Adverse Effects
Headache, pharyngitis, upper respiratory tract infection, rhinitis.149
Interactions for QVAR
Metabolized by CYP3A4.149
Drugs Affecting Hepatic Microsomal Enzymes
Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations).a
Inducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations).a
Specific Drugs
Drug | Interaction | Comments |
|---|---|---|
Antidiabetic agents | May increase blood glucose concentrations in patients with diabetes mellitus | Adjust insulin and/or oral hypoglycemic dosages as needed |
NSAIAs | Possible increased risk of GI ulcerationa Decreased serum salicylate concentrationsa When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxicationa | Use salicylates and corticosteroids concurrently with cautiona Observe patients receiving both drugs closely for adverse effects of either druga May be necessary to increase salicylate dosage when corticosteroids are administered concurrently or decrease salicylate dosage when corticosteroids are discontinueda |
Vaccines and Toxoids | May cause a diminished response to toxoids and live or inactivated vaccinesa May potentiate replication of some organisms contained in live, attenuated vaccinesa Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages) a | Generally defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinueda May need serologic testing to ensure adequate antibody response for immunizationa Additional doses of the vaccine or toxoid may be necessarya May undertake immunization procedures in patients receiving nonimmunosuppressive doses of glucocorticoids or in patients receiving glucocorticoids as replacement therapy (e.g., Addison’s disease)a |
QVAR Pharmacokinetics
Absorption
Bioavailability
Absorbed into circulation following oral inhalation, 149 with peak plasma concentrations usually attained at 0.5 hour.149 After oral inhalation, 51–60% of the dose is deposited in the respiratory tract.154
Onset
Relief of respiratory symptoms usually is evident within 24 hours; however, about 1–4 weeks of continuous therapy may be required for optimum effectiveness.149
Distribution
Extent
Glucocorticoids cross the placenta and are distributed into milk.144 149 a No evidence of tissue storage of parent drug or metabolites.149
Elimination
Metabolism
Metabolized to active metabolites via CYP3A4.149
Elimination Route
Beclomethasone dipropionate and its metabolites eliminated principally in feces and to a lesser extent in the urine (<10%).149
Half-life
2.8 hours.149
Stability
Storage
Oral Inhalation
25°C (may be exposed to 15–30°C).149
Do not puncture aerosol containers, use or store near heat or an open flame, expose to temperatures >49°C, or place into a fire or incinerator for disposal.1 112 113 144 149
ActionsActions
Potent glucocorticoid and minimal mineralocorticoid activity.149 a c At recommended dosages, provides less than normal physiologic amounts of glucocorticoid systemically.149
Inhibits inflammatory cells and release of inflammatory mediators in the respiratory tract.149 Improves lung function (e.g., forced expiratory volume in 1 second [FEV1], morning peak expiratory flow).149
Principal sites of action are the bronchi and bronchioles.149
May reduce the following: number of mediator cells (basophils, leukocytes, and mast cells) at the epithelial level, number of eosinophils, sensitivity of sensory nerves to mechanical stimuli, secretory response to cholinergic receptor stimulation, and fibroblast activity.c
May inhibit capillary dilation and permeability, stabilize lysosomal membranes, and prevent subsequent release of proteolytic enzymes.c
Advice to Patients
Importance of providing the patient a copy of the manufacturer's patient information.149
Importance of understanding of proper storage, preparation, and administration techniques.149 b
Advise that oral inhalation must be used at regular intervals to be therapeutically effective.100 103 144 149
Importance of understanding that although improvement may occur within the first 24 hours, at least 1–4 weeks of continuous therapy may be required for optimal effectiveness.1 2 61 77 100 112 113 144 149
Importance of rinsing the mouth after inhalation and not exceeding the recommended dosage.1 2 71 112 113 144 149 b
Importance of not using orally inhaled beclomethasone dipropionate as a bronchodilator or for emergency use (e.g., relief of acute bronchospasm).1 2 103 112 113 144 149
Importance of contacting a clinician immediately when asthmatic attacks that are not controlled by bronchodilator therapy occur.1 2 112 113 149
Advise patients being transferred from systemic corticosteroid to beclomethasone dipropionate oral inhalation therapy to carry special identification (e.g., card, bracelet) indicating the need for supplementary systemic corticosteroids during periods of stress. (See Concomitant Therapy under Cautions.)1 2 112 113 144 149
Importance of immunosuppressed patients avoiding exposure to certain infections (e.g., chickenpox, measles) and if exposed, of immediately consulting their clinician.113 134 135 136 142 143 144 149
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.149
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.149
Importance of advising patients of other important precautionary information.149 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral Inhalation | Aerosol | 40 mcg/metered spray | QVAR Oral Inhaler (with fluoroethane propellants and ethanol) | IVAX |
80 mcg/metered spray | QVAR Oral Inhaler (with fluoroethane propellants and ethanol) | IVAX |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Beconase AQ 42MCG/SPRAY Suspension (GLAXO SMITH KLINE): 25/$149.99 or 75/$415.97
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions July 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Schering Corporation. Vanceril 42 mcg (beclomethasone dipropionate, 42 mcg) inhalation aerosol prescribing information. Kenilworth, NJ; 2000 Aug.
2. Glaxo Wellcome. Beclovent (beclomethasone dipropionate) inhalation aerosol prescribing information. Research Triangle Park, NC; 1997 Dec.
3. Schering Corporation. Vanceril basic data book. Kenilworth, NJ; 1976 May.
4. Harris DM. Clinical pharmacology of beclomethasone dipropionate. In: Mygind N, Clark TJH, eds. Topical steroid treatment for asthma and rhinitis. London: Bailliere Tindall; 1980:34-47.
5. Wade A, ed. Martindale: the extra pharmacopeia. 27th ed. London: The Pharmaceutical Press; 1977:401-2.
6. Bondarevsky E, Shapiro MS, Schey G et al. Beclomethasone dipropionate use in chronic asthmatic patients: effect on adrenal function after substitution for oral glucocorticoids. JAMA. 1976; 236:1969-71. [IDIS 64768] [PubMed 989561]
7. Smith AP, Booth M, Davey AJ. A controlled trial of beclomethasone dipropionate for asthma. Br J Dis Chest. 1973; 67:208-14. [PubMed 4580987]
8. Harvey LL, Nair SV, Kass I. Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthma. Chest. 1976; 70:345-50. [IDIS 77953] [PubMed 782796]
9. Pines A. Beclomethasone dipropionate used as an aerosol in the treatment of asthma. Practitioner. 1975; 211:86-90.
10. Cayton RM, Soutar CA, Stanford CF et al. Double-blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol in the treatment of chronic bronchial asthma. Lancet. 1974; 2:303-7. [PubMed 4136046]
11. Brown HM, Storey G. Beclomethasone dipropionate steroid aerosol in the treatment of perennial allergic asthma in children. Br Med J. 1973; 3:161-4. [IDIS 37188] [PubMed 4352726]
12. Dickson W, Hall CE, Ellis M et al. Beclomethasone dipropionate aerosol in childhood asthma. Arch Dis Child. 1973; 48:671-5. [IDIS 47206] [PubMed 4354778]
13. Gwynn CM, Smith JM. A one year follow-up of children and adolescents receiving regular beclomethasone dipropionate. Clin Allergy. 1974; 4:325-30.
14. Kerrebijn KF. Beclomethasone dipropionate in long-term treatment of asthma in children. J Pediatr. 1976; 89:821-6. [IDIS 79822] [PubMed 789844]
15. Vogt F, Chervinsky P, Dwek J et al. Beclomethasone dipropionate aerosol in the treatment of chronic bronchial asthma. J Allergy Clin Immunol. 1976; 58:316-21. [IDIS 75020] [PubMed 780407]
16. Choovoravech P, Preeyasombat C. Trial of beclomethasone dipropionate aerosol in the treatment of severe chronic asthma. Practitioner. 1978; 220:639-42. [IDIS 99093] [PubMed 349536]
17. Klein R, Waldman D, Kershnar H et al. Treatment of chronic childhood asthma with beclomethasone dipropionate aerosol. Part I: a double-blind crossover trial in nonsteroid-dependent patients. Pediatrics. 1977; 60:7-13. [IDIS 89666] [PubMed 327424]
18. Mackay JB. The impact of beclomethasone dipropionate aerosol on patients with reversible airways obstruction attending a chest clinic. Postgrad Med J. 1975; 51(Suppl 4):37-41. [PubMed 812073]
19. Zwi S, Van As A, Goldman HI et al. The measurement of response to beclomethasone dipropionate treatment for asthma. Postgrad Med J. 1975; 51(Suppl 4):64-7. [PubMed 1105521]
20. Johannessen H, Halvorsen FJ, Kommedal TM. Long-term treatment of patients with perennial bronchial asthma with beclomethasone dipropionate aerosol: a 24 month follow-up study. Curr Ther Res. 1979; 26:592-600.
21. Vandenberg R, Tovey E, Love I et al. Beclomethasone dipropionate: trial of a new inhalational steroid preparation in the treatment of steroid-dependent chronic asthmatics. Med J Aust. 1975; 1:189-93. [IDIS 51266] [PubMed 1128399]
22. Webb DR. Corticosteroid aerosols in the treatment of asthma. Bull Mason Clin. 1975; 29:98-106.
23. Brown HM, Storey G, George WHS. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972; 1:585-90. [IDIS 24974] [PubMed 4335298]
24. Bacal E, Patterson R. Long-term effects of beclomethasone dipropionate on prednisone dosage in the corticosteroid asthmatic. J Allergy Clin Immunol. 1978; 62:72-5. [IDIS 115339] [PubMed 670607]
25. Richards W, Platzker A, Church JA et al. Steroid-dependent asthma treated with inhaled beclomethasone dipropionate in children. Ann Allergy. 1978; 41:274-7. [IDIS 118451] [PubMed 362991]
26. Toogood JH, Lefcoe NM, Haines DSM et al. Minimum dose requirements of steroid-dependent asthmatic patients for aerosol beclomethasone and oral prednisone. J Allergy Clin Immunol. 1978; 61:355-64. [IDIS 98988] [PubMed 659727]
27. Kershnar H, Klein R, Waldman D et al. Treatment of chronic childhood asthma with beclomethasone dipropionate aerosols. Part II: effect on pituitary-adrenal function after substitution for oral corticosteroids. Pediatrics. 1978; 62:189-97. [IDIS 115288] [PubMed 358120]
28. Anon. Beclomethasone dipropionate (Vanceril) for asthma. Med Lett Drugs Ther. 1976; 18:76. [PubMed 958155]
29. Anon. Steroid aerosols for asthma. Med Lett Drugs Ther. 1975; 17:88. [PubMed 1186604]
30. Ballin JC. Evaluation of a new aerosolized steroid for asthma therapy. JAMA. 1976; 236:2891-3. [IDIS 66616] [PubMed 1036594]
31. Willey RF, Godden DJ, Carmichael J et al. Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma. Br J Dis Chest. 1982; 76:61-8. [PubMed 7037035]
32. Kennedy MCS, Posner E, Thursby-Pelham DC. Long-term treatment of asthma with beclomethasone dipropionate. Postgrad Med J. 1975; 51(Suppl 4):84-6. [PubMed 812075]
33. Williams MH Jr. Beclomethasone dipropionate. Ann Intern Med. 1981; 95:464-7. [IDIS 138411] [PubMed 6792963]
34. Shim C, Stover DE, Williams MH Jr. Response to corticosteroids in chronic bronchitis. J Allergy Clin Immunol. 1978; 62:363-7. [IDIS 120228] [PubMed 361794]
35. Elkon KB, Sher R, Seftel HC. Immunological studies of eosinophilic gastroenteritis and treatment with disodium cromoglycate and beclomethasone dipropionate. S Afr Med J. 1977; 52:834-41.
36. Kumana CR, Meghji M, Seaton T et al. Beclomethasone dipropionate enemas for treating inflammatory bowel disease without producing Cushing’s syndrome or hypothalamic-pituitary-adrenal suppression. Lancet. 1982; 1:579-83. [IDIS 146782] [PubMed 6121181]
37. Matthews JI, Hooper RG. Idiopathic bronchial stenosis in a young woman. Chest. 1978; 74:690-1. [IDIS 118949] [PubMed 738131]
38. Horton DJ, Spector SL. Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol. Chest. 1977; 71:540-2. [IDIS 84064] [PubMed 852327]
39. Andersson E, Smidt CM, Sikjaer B et al. Bronchial biopsies after beclomethasone dipropionate aerosol. Br J Dis Chest. 1977; 77:35-43.
40. Mellis CM, Phelan PD. Asthma deaths in children—a continuing problem. Thorax. 1977; 32:29-34. [PubMed 841530]
41. Bhan GL, Gwynn CM, Smith JM. Growth and adrenal function of children on prolonged beclomethasone dipropionate treatment. Lancet. 1980; 1:96-7. [IDIS 108713] [PubMed 6101444]
42. Smith JM. Hazards of prolonged use of beclomethasone spray. JAMA. 1982; 248:1449. [IDIS 156419] [PubMed 7109163]
43. Siegel SC, Katz RM, Rachelefsky GS. Prednisone and beclomethasone for treatment of asthma. N Engl J Med. 1979; 300:986. [IDIS 93832] [PubMed 431575]
44. Clark TJH. Beclomethasone dipropionate treatment of asthma in adults. In: Mygind N, Clark TJH, eds. Topical steroid treatment for asthma and rhinitis. London: Bailliere Tindall; 1980:94-106.
45. Wyatt R, Waschek J, Weinberger M et al. Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. N Engl J Med. 1978; 299:1387-92. [IDIS 91444] [PubMed 362207]
46. Vaz R, Senior B, Morris M et al. Adrenal effects of beclomethasone inhalation therapy in asthmatic children. J Pediatr. 1982; 100:660-2. [IDIS 148471] [PubMed 7062222]
47. Toogood JH, Lefcoe NM, Haines DSM et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol. 1977; 59:298-308. [IDIS 86371] [PubMed 321503]
48. Toogood JH, Jennings B, Greenway RW et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol. 1980; 65:145-53. [IDIS 113987] [PubMed 7351447]
49. Chiu JT, Wells I, Novey HS. Incidence of fungal precipitins in patients treated with beclomethasone dipropionate aerosol. Ann Allergy. 1981; 46:137-9. [IDIS 134708] [PubMed 7008662]
50. Milne LJR, Crompton GK. Beclomethasone dipropionate and oropharyngeal candidiasis. Br Med J. 1974; 3:797-8. [IDIS 47946] [PubMed 4606264]
51. Stein MR, Shay SS, Jacobson K. Monilial esophagitis in asthmatic patients treated with beclomethasone. J Allergy Clin Immunol. 1979; 63:172.
52. Imbeau SA, Geller M. Aerosol beclomethasone treatment of chronic severe asthma—a one-year experience. JAMA. 1978; 240:1260-2. [IDIS 85908] [PubMed 682308]
53. Klotz LR, Klotz SD, Moeller RK. The use of beclomethasone dipropionate inhaler complicated by the development of an eosinophilic pneumonia reaction. Ann Allergy. 1977; 39:133-6. [IDIS 90762] [PubMed 889156]
54. Hudgel DW, Spector SL. Pulmonary infiltration with eosinophilia—recurrence in an asthmatic patient treated with beclomethasone dipropionate. Chest. 1977; 72:359-60. [IDIS 92254] [PubMed 891289]
55. Friedman H, Tworag JF, Voss HE et al. Eosinophilic pneumonia in association with the use of beclomethasone dipropionate aerosol. J Allergy Clin Immunol. 1978; 61:150.
56. Brogden RN, Pinder RM, Sawyer PR et al. Beclomethasone dipropionate inhaler: a review of its pharmacology, therapeutic value and adverse effects. Part I: asthma. Drugs. 1975; 10:166-210. [IDIS 62498] [PubMed 172309]
57. Bryant DH, Pepys J. Bronchial reactions to aerosol inhalant vehicle. Br Med J. 1976; 1:1319-20. [PubMed 1268679]
58. Kass I, Nair SV, Patil KD. Beclomethasone dipropionate aerosol treatment of steroid-dependent asthmatic patients: an assessment of 18 months of therapy. Chest. 1977; 71:703-7. [IDIS 81635] [PubMed 405181]
59. Lee-Hong E, Collins-Williams C. The long-term use of beclomethasone dipropionate for the control of severe asthma in children. Ann Allergy. 1977; 38:242-4. [PubMed 851256]
60. Cooper EJ, Grant IWB. Beclomethasone dipropionate aerosol in treatment of chronic asthma. Q J Med. 1977; 46:295-308. [IDIS 90416] [PubMed 918249]
61. USPDI: 1983 drug information for the health care provider. Johnson KW, ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1983; I:177-8.
62. Freigang B. New method of beclomethasone aerosol administration to children under 4 years of age. Can Med Assoc J. 1977; 117:1308-9. [IDIS 75131] [PubMed 922624]
63. Freigang B. Long-term follow-up of infants and children treated with beclomethasone aerosol by a special inhalation device. Ann Allergy. 1980; 45:13-7. [IDIS 119650] [PubMed 6773446]
64. Soderberg-Warner M, Siegel S, Katz R et al. Treatment of chronic childhood asthma with beclomethasone dipropionate aerosols (BDP). IV. long-term effects on growth. J Allergy Clin Immunol. 1979; 63:164.
65. Godfrey S, Balfour-Lynn L, Tooley M. A three- to five-year follow-up of the use of the aerosol steroid beclomethasone dipropionate, in childhood asthma. J Allergy Clin Immunol. 1978; 62:335-9. [IDIS 120226] [PubMed 712019]
66. Godfrey S. Beclomethasone dipropionate treatment of childhood asthma. In: Mygind N, Clark TJH, eds. Topical steroid treatment for asthma and rhinitis. London: Bailliere Tindall; 1980:123-36.
67. Anon. Management of asthma in the child aged under 6 years. BMJ. 1981; 283:863-4.
68. Schering Corporation. Vancenase prescribing information. Kenilworth, NJ; 1981 Sep.
69. Glaxo Inc. Beconase prescribing information. Fort Lauderdale, FL; 1981 Aug.
70. Brown HM, Storey G. Beclomethasone dipropionate aerosol in long-term treatment of perennial and seasonal asthma in children and adults: a report of five-and-half years experience in 600 asthmatic patients. Br J Clin Pharmacol. 1977; 3(Suppl):259-67S.
71. Schering Corporation. Vanceril oral inhaler patient instructions. Kenilworth, NJ; 1978 Aug.
72. Iezzoni DG (Schering Corporation, Kenilworth, NJ): Personal communication; 1982 Jul.
73. Gregg I. The importance of patient education in the
No comments:
Post a Comment